Provider: View Press Release
Type: Link
Title: GSK’s respiratory syncytial virus older adult vaccine candidate granted Priority Review by US FDA | GSK
Description: The US FDA has accepted a Biologics License Application and granted Priority Review for its RSV older adult vaccine candidate.
Provider: Gsk
Type: JPG
Provider: View Press Release
Type: Link
Title: European Medicines Agency validates ViiV Healthcare’s marketing authorisation application for cabotegravir long-acting injectable for HIV Prevention | GSK
Description: The marketing application is based on results from the HPTN 083 and 084 phase IIb/III studies.
Provider: View Press Release
Type: Link
Title: GSK marketing authorisation application for respiratory syncytial virus older adult vaccine candidate accepted by European Medicines Agency under accelerated assessment | GSK
Description: The vaccine was well tolerated with a favourable safety profile.
Provider: View Press Release
Type: Link
Title: GSK provides update on ContRAst phase III programme for otilimab in the treatment of moderate to severe rheumatoid arthritis | GSK
Description: Full results from the ContRAst phase III programme will be submitted for publication in 2023.
Provider: View Press Release
Type: Link
Title: GSK reports outcome from US FDA Advisory Committee meeting on daprodustat for anaemia of CKD | GSK
Description: Daprodustat was studied in the ASCEND phase III clinical trial programme.